Biomarker ID | 1272 |
PMID | 24371517 |
Year | 2013 |
Biomarker | Integrin α3 [ITGA3] |
Biomarker Basis | Expression Based |
Biomolecule | Protein |
Source | Urine |
Subjects | Humans |
Regulation | Upregulated in Metastatic Prostate Cancer |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | Pathways include: Dilated cardiomyopathy, Hematopoietic cell lineage, Cell surface interactions at the vascular wall, Integrin-mediated cell adhesion, Integrin cell surface interactions |
Experiment | Metastasis Vs Prostate Cancer and BPH |
Type of Biomarker | Diagnostic |
Cohort | Patients with Benign Prostatic Hyperplasia BPH (n=5), Prostate Cancer PCa (n=5) and metastatic PCa (n=3) were selected for evaluation of protein expression in the exosomes |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.005 |
Method Used | Western Blotting |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Validated on Human Patient Cohort |
Technical Name | ITGA3 |